Cancer patients get chance to continue promising drug in Long-Term safety study
Disease control
Completed
This study allowed patients with various cancers who had benefited from the drug tazemetostat in earlier trials to continue receiving it. The main goal was to monitor the drug's long-term safety in these patients. It was open to people who had not seen their cancer worsen and cou…
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC